Kurt Muhammed Mustafa, Çekiç Osman, Akpolat Çetin, Aslankurt Murat, Elçioğlu Mustafa Nuri
Department of Ophthalmology, Okmeydanı Training and Research Hospital, Istanbul, Turkey.
Ophthalmologica. 2017;238(3):147-153. doi: 10.1159/000477180. Epub 2017 Jun 10.
The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD).
Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR).
In the ranibizumab group, the mean CRAE value decreased significantly at 1 week and 1 month (p = 0.002). The AVR value decreased significantly at 1 month (p = 0.028). CRVE values did not change at 1 week and 1 month (p = 0.083). In the bevacizumab group, the preinjection CRAE, CRVE, and AVR values did not change through the study period (p = 0.128, p = 0.600, and p = 0.734, respectively).
These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD.
本文旨在评估和比较玻璃体内注射雷珠单抗和贝伐单抗对新生血管性年龄相关性黄斑变性（AMD）患者视网膜血管直径的影响。
纳入接受玻璃体内注射雷珠单抗或贝伐单抗的新生血管性AMD患者。未注射的对侧眼作为对照。主要观察指标为视网膜中央动脉等效直径（CRAE）、视网膜中央静脉等效直径（CRVE）和动静脉比（AVR）。
在雷珠单抗组，1周和1个月时平均CRAE值显著降低（p = 0.002）。1个月时AVR值显著降低（p = 0.028）。1周和1个月时CRVE值未发生变化（p = 0.083）。在贝伐单抗组，整个研究期间注射前的CRAE、CRVE和AVR值均未发生变化（分别为p = 0.128、p = 0.600和p = 0.734）。
这些结果表明，玻璃体内注射雷珠单抗可导致新生血管性AMD患者视网膜小动脉显著血管收缩。
